Latest Us Expansion News

Xero Limited has agreed to acquire Melio Limited, a leading US SMB bill pay platform, for US$2.5 billion, marking a significant leap in its US growth strategy. The deal is backed by a substantial A$1.85 billion equity raise and aims to accelerate revenue and market presence by FY28.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

Kip McGrath Education Centres announces exit from its unprofitable USA operations while reporting improved underlying EBITDA for FY25, alongside CEO transition costs and property lease provisions.

The Calmer Co. International Limited has launched its Taki Mai kava tinctures on Amazon USA, marking a strategic expansion into a rapidly growing wellness segment. This move aims to capitalize on the booming US tincture market and strengthen the company’s foothold in natural relaxation products.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Adveritas Limited has raised $8.5 million through an oversubscribed institutional placement, positioning itself for expansion into the US market and accelerated product development.

Singular Health Group has inked a $1.3 million contract with Provider Network Solutions to deploy its 3DICOM imaging platform across key US states, backed by an $8 million capital raise to fuel national expansion.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

Australian Strategic Materials (ASM) has announced an underwritten share purchase plan to raise up to A$3 million, supporting its advancing Dubbo Project and ramp-up of the Korean Metals Plant. The company also outlines ambitions for a US metals facility amid strong government backing and strategic partnerships.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.

Silver Mines Limited has secured two historic Californian projects, Calico North and Kramer Hills, adding significant silver and gold exploration potential to its portfolio with minimal upfront cash outlay.

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.